Safety of dupilumab in moderate-to-severe atopic dermatitis: Clinical laboratory results from three phase 3 clinical trials (LIBERTY AD: SOLO 1, SOLO 2 and CHRONOS)-MedSci.cn

Safety of dupilumab in moderate-to-severe atopic dermatitis: Clinical laboratory results from three phase 3 clinical trials (LIBERTY AD: SOLO 1, SOLO 2 and CHRONOS)

Wollenberg, A; Blauvelt, A; Simpson, EL; Chen, Z; Shumel, B; Khokhar, FA; Hultsch, T; Rizova, E; Rossi, A; Graham, NMH; Pirozzi, G; Lu, Y; Ardeleanu, M

ALLERGY, 2018; 73 (): 77

科室
- - 订阅+
  - 更多科室
工具
服务